ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Mahamaya Lifesciences will hold a board meeting on November 13, 2026 to consider unaudited standalone and consolidated results for the half year ended September 30, 2026. The trading window stays closed until November 16, 2026.
Mahamaya Lifesciences Ltd, an SME-platform listed company, confirms non-applicability of Corporate Governance under Regulation 27(2) for the quarter ended 30 September 2026. A Company Secretary certificate is enclosed.
Mahamaya Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations.
Mahamaya Lifesciences announced the publication of an executive interview in AgroPages Magazine (2026 India Focus Issue), highlighting operational progress and strategic growth initiatives.
Mahamaya Lifesciences Limited announced management changes including the appointment of Dr. Bhagirath Choudhary and re-appointment of two Independent Directors. The MD and Executive Director were also re-designated.
Mahamaya Lifesciences Limited held its 24th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and management re-designations.
Promoter Prashant Krishnamurthy acquired 7,200 equity shares of Mahamaya Lifesciences Ltd through open market purchases on BSE.
Mahamaya Lifesciences Limited has filed its Annual Report for the financial year 2025-26. The document details the company's financial and operational performance.
Mahamaya Lifesciences Limited has issued the notice for its Annual General Meeting scheduled on September 29, 2026. The agenda includes financial adoption and various director appointments.
Mahamaya Lifesciences announced major leadership changes including the appointment of Mr. Amarendra Mohapatra as CFO and Mr. Kush Mishra as Company Secretary, effective November 2026 and August 2025 respectively.
Mahamaya Lifesciences announced the resignation of Ms. Shilpi Bhardwaj from her position as Company Secretary, Compliance Officer, and Key Managerial Personnel.
Mahamaya Lifesciences reported FY26 revenue of ₹328.87 Crore, representing 24.5% year-on-year growth. EBITDA rose 32.06%, reflecting strong operational performance and improved business momentum.
Mahamaya Lifesciences Ltd reported revenue from operations of ₹165.8 Cr and net profit of ₹8.2 Cr for H2 FY26.
Mahamaya Lifesciences reported annual consolidated total income of ₹330.03 Crore for FY2026. The Board approved audited results, reflecting the company's first full-year performance as a listed entity.
Mahamaya Lifesciences scheduled a board meeting for May 25, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-declaration.
Mahamaya Lifesciences Limited has been awarded the "Quality Excellence Award-Adherence to Global Quality Standards (GMP)" by Business Connect. The recognition highlights the company's commitment to global manufacturing standards and quality excellence. This award serves as a positive validation of the company's operational processes and quality management systems.
Mahamaya Lifesciences Limited has been awarded the 'Great Place to Work' certification in India for the 'Under 100 Employees' category. The certification is valid from April 2026 to April 2027, recognizing the company's commitment to building a high-trust, high-performance workplace culture.
Mahamaya Lifesciences Ltd informed BSE that it is exempt from filing quarterly Corporate Governance Reports under Regulation 27(2) of SEBI LODR. This exemption applies as the company is listed on the BSE SME Platform and fulfills criteria under Regulation 15(2). This is a routine regulatory compliance notification.
Mahamaya Lifesciences Ltd submitted its annual declaration under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The promoter and promoter group confirmed that no encumbrances were created on their shareholding during the period. This routine compliance filing affirms stable promoter holding and absence of fresh pledges.